The chemical compound identified by CAS number 401566-79-8, commonly known as 1-(3-Methyl-1-phenyl-5-pyrazolyl)piperazine, plays a significant role in the pharmaceutical industry. As a specialized intermediate, its chemical structure and properties make it a vital component in the synthesis of important pharmaceutical products, most notably Teneligliptin, an orally active DPP-4 inhibitor used for treating Type II diabetes.

Detailed analysis of the compound reveals its molecular formula as C14H18N4 and a molecular weight of 242.32. It is typically supplied as an off-white to pale beige solid, with a guaranteed purity of 98.0% or higher. These characteristics are critical for its intended use in complex pharmaceutical syntheses, where consistency and minimal impurities are paramount. Researchers and procurement specialists often look for this specific CAS number to ensure they are sourcing the correct material.

When looking to buy 1-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazine, understanding its primary application as a Teneligliptin intermediate is essential. This demand drives the market for high-quality materials, making reliable suppliers and competitive prices crucial. Pharmaceutical companies are keen to establish partnerships with manufacturers who can guarantee the stability of the CAS 401566-79-8 supply chain.

The significance of this compound also extends to its potential use as a building block in broader medicinal chemistry research, exploring new heterocyclic derivatives and their therapeutic applications. Its availability from reputable chemical manufacturers in China offers a cost-effective solution for both research and large-scale production needs.

In essence, CAS 401566-79-8, 1-(3-Methyl-1-phenyl-5-pyrazolyl)piperazine, represents more than just a chemical identifier; it signifies a critical link in the pharmaceutical supply chain. By focusing on purity, supplier reliability, and precise chemical specifications, companies can effectively leverage this intermediate for developing and manufacturing advanced therapeutic agents.